Genomic Press’ Post

*SPRAVATO AS MONOTHERAPY FOR TRD!* Patients on Spravato for treatment resistant depression may soon no longer need to take an oral antidepressant…. My clinical experience all these years has been validated by this research poster presented Psych Congress 2 weeks ago Here are highlights from the poster: Esketamine Nasal Spray for Treatment-Resistant Depression -Study Context: A randomized, double-blind study presented at Psych Congress 2024 examined esketamine nasal spray monotherapy in adults with treatment-resistant depression. -Participant Criteria: Adults with major depressive disorder (MDD) with no psychotic features, high depressive symptom scores, and nonresponse to ≥2 oral antidepressants (OADs) were included. -Study Design: After a 2-week OAD-free period, participants (n=378) were randomized (2:1:1) to placebo or ESK doses (56mg/84mg) twice weekly for 4 weeks. -Key Findings: -Primary Endpoint: Mean change in MADRS score at day 28 was significantly better for ESK vs. placebo (56mg: −5.1, 84mg: −6.8; P< 0.001). -Secondary Endpoint: At day 2, MADRS score changes for ESK (56mg: p=0.004; 84mg: P=0.006) also outperformed placebo. -Safety Profile: Common adverse events (≥10%) included nausea, dissociation, dizziness, and headache. No new safety concerns emerged. The full manuscript has been submitted to JAMA, Journal of the American Medical Association Psychiatry and if accepted and published, will be out in 2025. Check out this article to learn more: https://lnkd.in/eEq3w5x9 • #PsychCongress2024 • #Esketamine • #TreatmentResistantDepression • #MentalHealthResearch • #Psychiatry • #ClinicalStudy • #DepressionTreatment • #EsketamineEfficacy • #MentalHealthAwareness • #InnovativeTherapies • #DepressionResearch • #Psychopharmacology

https://lnkd.in/g5qk52NU                                                                    Article title: Comparison of two questionnaires (PDQ-39 and SEIQoL) for assessment of the quality of life in idiopathic Parkinson’s disease   Author(s): Lena Waldvogel; Ketevan Toloraia; Peter Fuhr; Ute Gschwandtner* Journal: Annals of Psychiatry and Treatment   Journal ISSN: 2640-8031 Abstract: Parkinson’s disease is a neurodegenerative disease of the central nervous system that begins insidiously and progresses over time with a loss of nerve cells in certain brain regions. People with chronic diseases often experience a change in their quality of life. For patients, relatives, and the whole community, a reduced quality of life can pose a significant burden. Therefore, it is imperative to reduce socioeconomic costs to preserve high health quality in patients with neurodegenerative disorders. Parkinson’s disease can cause people to have difficulty performing daily activities such as working or shopping. It is not uncommon for social interaction to be impaired, as patients sometimes struggle to participate in social life due to their symptomatology. The quality of life of Parkinson’s disease patients can be measured in different ways. A distinction can be made between Health-related Quality of Life and Individualised Quality of Life. Several questionnaires and screening tools are investigating the Quality of Life in patients with Parkinson’s disease. However, their validity and practicability are often not extensively analyzed. #ParkinsonsDisease #PDQ39 #SEIQoL #QualityOfLife #Neurodegeneration #BiologicalPsychiatry #Psychopharmacotherapy #PsychologicalMedicine #ForensicPsychiatry #SocialPsychiatry #Sociotherapy #PTSD #Peertechz #PeertechzPublications #ChildAndAdolescentPsychiatry #AddictionPsychiatry #MoodDisorders #Nosography #Schizophrenia

https://lnkd.in/gWu7Zzwg                                                             Article title: Perrotta Integrative Clinical Interviews (PICI-2): Innovations to the first model, the study on the new modality of personological investigation, trait diagnosis and state diagnosis, and the analysis of functional and dysfunctional personality traits. An integrated study of the dynamic, behavioural, cognitive and constructivist models in psychopathological diagnosis. Research   Author(s): Giulio Perrotta Journal: Annals of Psychiatry and Treatment   Journal ISSN: 2640-8031 Abstract: Purpose: As a result of clinical findings it is necessary to make some changes to the previous model, the first version. The second version of the PICI model (Perrotta Integrative Clinical Interviews) improves the previous version by introducing some interpretative corrections, especially with regard to dysfunctional hyperactivation, unitary diagnosis, symptomatological persistence, categorical absorption, trait diagnosis and state diagnosis, egosyntony and egodystonia, reducing the items from 150 to 128 for the PICI-2C questionnaire and from 195 to 173 for the PICI-2TA questionnaire. The second version of the PICI is also enriched by a third questionnaire, PICI-2FT, always administered by the therapist after the clinical interview, with 18 items, capable of investigating functional personality traits and thus completing in a more descriptive way the personality picture of the patient in its functional and structural totality. #PersonalityDisorders #PICI1 #PICI2 #MMPIIII #BiologicalPsychiatry #Psychopharmacotherapy #PsychologicalMedicine #ForensicPsychiatry #SocialPsychiatry #Sociotherapy #PTSD #Peertechz #PeertechzPublications #ChildAndAdolescentPsychiatry #AddictionPsychiatry #MoodDisorders #Nosography #Schizophrenia

"The conference will highlight a paradigm shift in medicine and the newfound recognition of immune dysregulation in some patients with OCD, psychosis, depression, anxiety, schizophrenia, and mental health conditions previously viewed solely through the lens of psychiatry. Attendees can expect a fresh perspective on mental health, with presentations on the role of neuroinflammation in some psychiatric deteriorations, the impact of immune dysregulation on mental health, and therapeutic strategies that leverage immunomodulation to address symptoms that have historically been treated primarily with psychotropics." #cme #cmecredits https://lnkd.in/e2zbZeWK

In the last 50-60 years, billions of dollars have been spent on identifying biomarkers for mental illnesses. Although there have been a few promising starts, most efforts have failed. This is not surprising, given the brain's monstrous complexity. In addition, factor in the mind-body interactions that govern almost every aspect of our mood, emotions, etc., and the problem grows even more complex. And then, throw the environment into the mix, and the complexity grows even more Will this study get it right? We can only wait and watch. My personal view is that the science of mind/psychiatry needs a 'revolution', not very different from the Theory of Relativity and Quantum Mechanics, which revolutionised physics and our understanding of the cosmos. #biomarkers #mentalhealth #psychiatry #brain

🎥 New Special Report! 🎥 We’re excited to present a special 5-part series on Embracing New Therapies in Schizophrenia Management, with insights from leading subject matter experts Rishi Kakar, MD, of Segal Trials, Andrew Cutler, MD, Neuroscience Education Institute, and moderator Sam Clark, MD PhD, of Terran Biosciences. In this series, we dive deep into the groundbreaking FDA-approved schizophrenia treatment, xanomeline and trospium chloride capsules (Cobenfiy; Bristol Myers Squibb), and its novel mechanism of action targeting muscarinic receptors instead of traditional dopamine pathways. The series highlights key clinical trial data, symptom management, and how these new therapies could revolutionize treatment for patients who haven't fully responded to traditional antipsychotics. Watch and learn how these advancements may shape the future of schizophrenia care, improve patient outcomes, and address unmet needs in managing this complex condition. In the segment below, the experts discuss the application of clinical trial data to real-world settings. Use the link for the full series! https://lnkd.in/eDvyx_9S #Schizophrenia #Neuropsychiatry #MentalHealth #Psychiatry

Efficacy and Tolerability of FDA-Approved Atypical Antipsychotics in Bipolar Depression 🚀 Bayesian network meta-analysis The analysis included 16 randomized controlled trials involving 7234 patients treated with one of five AAPs: 1. Cariprazine 2. Lumateperone 3. Lurasidone 4. Olanzapine 5. Quetiapine. 👉All AAPs demonstrated greater efficacy than placebo in improving depression 👉Cariprazine, lurasidone, olanzapine, and quetiapine were more effective than placebo in achieving remission Tolerability and Adverse Events: 👉Olanzapine showed lower odds of all-cause discontinuation compared to placebo, suggesting better overall tolerability. 👉Quetiapine had higher odds of discontinuation due to adverse events. 👉Lumateperone, olanzapine, and quetiapine were associated with higher odds of causing somnolence than placebo. 👉Lumateperone had a lower incidence of significant weight gain (≥7%) compared to other AAPs and placebo. 👉Olanzapine was linked to significant increases in total cholesterol and triglycerides. Paper 👉 Li S, Xu C, Hu S, Lai J. Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. Eur Psychiatry. 2024 #bipolardepression #bipolardisorder #psychiatry #psychopharmacology

There are 6 forms of depression, study shows. Here’s how they’re different. “Of the nearly 1 in 5 people in the United States suffering from depression, many aren't properly diagnosed and end up receiving treatment in a trial-and-error manner, which can be costly, ineffective, frustrating, and, in some cases, damaging. Now, research scientists at Stanford aim to change that by identifying unique biomarkers for each type of depression to match them with targeted treatment.  Their findings, recently published in a Nature Medicine study, show the results of machine learning and brain imaging in hundreds of patients while doing specific tasks and at rest—helping the team identify six distinct subtypes of depression.” Read the full article here: https://buff.ly/4dnsj4A Read the full PDF article here: https://buff.ly/46x4ntu #MentalHealthAwareness #trauma #ptsd #MDMA #addiction #depression #psilocybin #psychiatry #psychology #psychedelictherapy #psychedelics #medicine #innovation #neuroscience

Psychiatric disorders may come and go with symptoms changing over a lifetime. This suggests the need for a paradigm shift in diagnosis and treatment. Here, a paper published in JAMA Psychiatry, presents a fresh look inspired by dynamical systems theory. This theory is used widely to explain tipping points, cycles, and chaos in complex systems ranging from the climate to ecosystems. The complexity of a multiplicity of morphing attractors mirroring lifelong roller coasters of psychiatric and neurological disorders may seem a bit overwhelming. What might be practical clinical applications? Are there examples? The authors show that in addition to providing a framework for making sense of the elusive nature of the spectrum of disorders, the dynamical systems view opens up 2 practical perspectives. First, one may use a quantitative toolbox for estimating dynamic resilience from time series that reflect fluctuations in behavior and mood in daily life over time. This may help detect the optimal timing for interventions. Second, one may detect individualized intervention targets using dynamical systems techniques to detect the feedbacks that stabilize the healthy state or disorders in any given person. Work in the field of dynamical systems points to novel ways of inferring causality and quantifying resilience from time series. Those approaches have now been tried and tested in a range of complex systems. The same tools may help monitoring and managing resilience of the healthy state as well as psychiatric disorders. Have a look at our paper "The Foundation and Architecture of Precision Medicine in Neurology and Psychiatry", recently published in Trends in Neuroscience: https://lnkd.in/ejAu7A7E JAMA Cell Press #neuroscience #psychiatry #neurology #neurologicaldisorders #psychiatricdisorders #alzheimersdisease #alzheimers #schizophrenia #bipolardisorder #depression #anxietydisorder #obsessivecompulsivedisorder #adhs #parkinsonsdisease #precisionmedicine #systemstheory #complexsystems #brainfunction #resilience #riskfactor #genetics #pathophysiology #causality #biomarkers #clinicalresearch #drugdevelopment #mentalhealth #vulnerability #aging #senescense #education #genetics #pathology #neuralnetworks #complexnetworks https://lnkd.in/e72ev7tD

https://lnkd.in/g-NFY8Gw                                                              Article title: Cariprazine in therapy of visual hallucinations. Randomized, double-blind placebo-controlled study   Author(s): NA Aliyev; ZN Aliyev Journal: Annals of Psychiatry and Treatment   Journal ISSN: 2640-8031 Abstract: Objective: We studied cariprazine in therapy of visual hallucinations with a therapeutic resistance due to traumatic brain injury randomized, double-blind placebo-controlled study manner. Methods: To traumatic brain injury hundred patients (100 all men) whom we studied were under observation in Mental Health Center of the Ministry of Health of the Republic of Azerbaijan from January 2020 to June 2021. The method of randomization was given by lottery []. Each patient was randomized to receive either in agreement of the instruction cariprazine (50 patients) over 5 day in dose 6 mg one times per os in morning after meet for 12 weeks or matched placebo (50 patients) in a double-blind manner. A structured clinical interview, for DSM-5Axis I Disorder, Patient Edition, was used to diagnose according to DSM-5 major or mild neurocognitive disorder due to traumatic brain injury. #Cariprazine #VisualHallucinations #TherapeuticResistance #TraumaticBrainInjury #BiologicalPsychiatry #Psychopharmacotherapy #PsychologicalMedicine #ForensicPsychiatry #SocialPsychiatry #Sociotherapy #PTSD #Peertechz #PeertechzPublications #ChildAndAdolescentPsychiatry #AddictionPsychiatry #MoodDisorders #Nosography #Schizophrenia